Analysts See $-0.70 EPS for Stemline Therapeutics, Inc. (STML); Dynegy (DYN) Shorts Up By 4.41%

April 17, 2018 - By Michael Collier

Dynegy Inc. (NYSE:DYN) Logo

Dynegy Inc (NYSE:DYN) had an increase of 4.41% in short interest. DYN’s SI was 17.65M shares in April as released by FINRA. Its up 4.41% from 16.90M shares previously. With 2.36 million avg volume, 8 days are for Dynegy Inc (NYSE:DYN)’s short sellers to cover DYN’s short positions. The SI to Dynegy Inc’s float is 17.57%. The stock decreased 2.51% or $0.33 during the last trading session, reaching $12.81. About 22.18M shares traded or Infinity% up from the average. Dynegy Inc. (NYSE:DYN) has risen 79.34% since April 17, 2017 and is uptrending. It has outperformed by 67.79% the S&P500.

Analysts expect Stemline Therapeutics, Inc. (NASDAQ:STML) to report $-0.70 EPS on May, 9.They anticipate $0.03 EPS change or 4.48% from last quarter’s $-0.67 EPS. After having $-0.93 EPS previously, Stemline Therapeutics, Inc.’s analysts see -24.73% EPS growth. The stock increased 1.74% or $0.3 during the last trading session, reaching $17.5. About 117,517 shares traded. Stemline Therapeutics, Inc. (NASDAQ:STML) has risen 79.53% since April 17, 2017 and is uptrending. It has outperformed by 67.98% the S&P500.

Dynegy Inc., through its subsidiaries, produces and sells electric energy, capacity, and ancillary services in the United States. The company has market cap of $1.85 billion. It operates in six divisions: PJM, NY/NE, ERCOT, MISO, IPH, and CAISO. It currently has negative earnings. The firm sells its services on a wholesale basis from its power generation facilities.

Investors sentiment decreased to 1.13 in 2017 Q4. Its down 0.39, from 1.52 in 2017Q3. It turned negative, as 48 investors sold Dynegy Inc. shares while 39 reduced holdings. 45 funds opened positions while 53 raised stakes. 135.98 million shares or 10.68% more from 122.86 million shares in 2017Q3 were reported. Warren Averett Asset Management Ltd Liability Company accumulated 1 shares or 0% of the stock. Hsbc Hldgs Public Ltd has 0% invested in Dynegy Inc. (NYSE:DYN). Westchester Cap Mgmt Lc owns 1.29M shares for 0.6% of their portfolio. Connecticut-based Point72 Asset Limited Partnership has invested 0% in Dynegy Inc. (NYSE:DYN). Stone Ridge Asset Mgmt Ltd Liability Corp owns 11,657 shares or 0.01% of their US portfolio. Suntrust Banks Inc invested 0% of its portfolio in Dynegy Inc. (NYSE:DYN). Fifth Third Bank accumulated 2 shares. State Board Of Administration Of Florida Retirement Sys invested 0% in Dynegy Inc. (NYSE:DYN). Macquarie Group Incorporated stated it has 2,900 shares. Fmr Ltd owns 7.65M shares for 0.01% of their portfolio. Kbc Nv holds 0% or 2,572 shares in its portfolio. The California-based Parallax Volatility Advisers Limited Partnership has invested 0% in Dynegy Inc. (NYSE:DYN). Penn Capital Mngmt Inc stated it has 1.6% of its portfolio in Dynegy Inc. (NYSE:DYN). Loring Wolcott And Coolidge Fiduciary Advsr Limited Liability Partnership Ma holds 0% or 1,200 shares in its portfolio. Bnp Paribas Arbitrage Sa holds 43,120 shares or 0% of its portfolio.

Among 14 analysts covering Dynegy (NYSE:DYN), 8 have Buy rating, 1 Sell and 5 Hold. Therefore 57% are positive. Dynegy had 50 analyst reports since August 9, 2015 according to SRatingsIntel. Barclays Capital maintained the stock with “Overweight” rating in Friday, March 18 report. As per Tuesday, October 31, the company rating was upgraded by Deutsche Bank. The firm has “Hold” rating given on Friday, October 27 by SunTrust. Deutsche Bank maintained it with “Buy” rating and $31 target in Friday, November 6 report. The stock has “Overweight” rating by Barclays Capital on Friday, May 20. Citigroup upgraded it to “Buy” rating and $19 target in Wednesday, June 29 report. As per Thursday, June 9, the company rating was downgraded by UBS. The firm earned “Hold” rating on Monday, January 22 by SunTrust. SunTrust maintained it with “Buy” rating and $19 target in Wednesday, August 24 report. The firm has “Neutral” rating given on Tuesday, February 21 by Goldman Sachs.

Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercialization of proprietary oncology therapeutics in the United States. The company has market cap of $487.27 million. The firm develops SL-401, a targeted therapy directed to the interleukin-3 receptor , which is in Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm, myeloproliferative neoplasms, and acute myeloid leukemia; and in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma. It currently has negative earnings. It also develops SL-801, a novel oral small molecule reversible inhibitor of a tumor-promoting nuclear transport protein, which is in Phase I clinical trial for the treatment of solid and hematologic cancers; and SL-701, an immunotherapy that is in Phase II clinical trial to attack brain cancer.

Since December 15, 2017, it had 0 insider buys, and 14 selling transactions for $2.80 million activity. The insider Hoberman Kenneth sold $514,085. Gionco David sold $23,399 worth of Stemline Therapeutics, Inc. (NASDAQ:STML) on Wednesday, March 7. Bergstein Ivan sold $656,439 worth of Stemline Therapeutics, Inc. (NASDAQ:STML) on Monday, March 12.

Dynegy Inc. (NYSE:DYN) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>